ArticleOrphanet journal of rare diseases2026
Use of the 10-meter timed walk for monitoring long-term gait progression in human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis: a 10-year analysis from the Japanese HAM-net registry.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic neuroinflammatory disease that affects approximately 0.3% of individuals with HTLV-1 infection in Japan. Considering the rarity of HAM/TSP, data on the natural progression of walking disability and its correlation with outcome measures, such as the Osame's Motor Disability Score (OMDS), remain limited. This observational study analyzed longitudinal data from the Japanese HAM patient registry "HAM-net" to identify appropriate clinical outcome measures for evaluating treatment efficacy in HAM/TSP.
methodsWe incorporated 10-meter timed walk (10mTW) data from patients registered in the HAM-net. The natural course of 10mTW performance was assessed, and its correlation with various outcome measures was analyzed to evaluate the use of the 10mTW as a primary outcome measure in HAM/TSP clinical trials.
resultsThis study included 142 patients with at least two 10mTW data; 77.5% were female, with a mean age at onset and HAM diagnosis of 45.7 and 53.8 years, respectively. The geometric mean (95% confidence interval [CI]) for the 10mTW at baseline, Year 5, and Year 10 was 12.6 s (95% CI, 11.5 s-13.8 s), 14.3 s (95% CI, 12.7 s-16.1 s), and 16.3 s (95% CI, 13.6 s-19.5 s), respectively. The 10mTW at Years 5 and 10 increased by 7.37% (95% CI, -0.39%-15.73%) and 42.10% (95% CI, 19.92%-68.39%), respectively. The 10mTW exhibited significant positive correlations with motor disability scores, such as the OMDS and Instituto de Pesquisa Clinica Evandro Chagas-1 (IPEC-1), and activities of daily living (ADL) scales, such as the Health Assessment Questionnaire (HAQ).
conclusionsThis study revealed a 42.10% increase in the 10mTW over 9 years, with significant correlations to motor disability scores (OMDS and IPEC-1) and ADL scales (HAQ). These findings support the use of 10mTW performance as a primary outcome measure in HAM/TSP clinical trials, emphasizing its value for long-term assessment of gait progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.